Register here for the
ADeN Journal Club &
Webinar Series

Shin Liau | Tiernan McDonough | Lina Okati | Nagham Ailabouni
ADeN Journal Club
Organising Committee

ADeN Journal Club & Webinar Series 2024

THU | 25 JULY | 11.00 AM AEST

The Deprescribing Meme
Prof David Le Couteur AO PhD
Professor of Geriatric Medicine Research, University of Sydney

How are deprescribing guidelines disseminated and implemented?
Mr Justin Cheng
Pharmacist and PhD candidate, University of Sydney

ADeN Journal Club & Webinar Series 2023


Join us for a Journal Club discussion of a recently published deprescribing article led by 
Mai Duong, MPhil, BScPharm, HBHSc
PhD Candidate, University of Sydney, Sydney, Australia

FRI | 13 OCTOBER | 11.00 AM AEDT

Medication Use at the End of Life in Residential Aged Care
Dr Kathleen Potter,MBChB, PhD
Research Facilitator, Ryman Healthcare, Christchurch, New Zealand

FRI | 25 AUGUST | 11.00 AM AEDT

Monoclonal antibodies to treat Alzheimer’s disease – do they pass the pub test?
Prof Ian Scott, MBBS, FRACP, MHA, MEd
Director, Princess Alexandra Hospital; Professor of Medicine, University of Queensland

ADeN Journal Club & Webinar Series 2022

FRI | 21 OCTOBER | 10.00 AM AEDT

Understanding influencing factors on general practitioners’ choices in prescribing analgesic medicines: a discrete choice experiment
Melanie Hamilton, BSc (Clin Sci), MPH
University of Sydney

Eliciting preferences for deprescribing antihypertensive medications among clinicians, carers and people living with dementia
Rakhee Raghunandan, BPharm, PGDipClinPharm, PhD
University of Sydney


Is There a Role for Pharmacoepidemiology in Deprescribing Research?

Caroline Sirois, PhD, Université Laval
Sascha Dublin, MD PhD, Kaiser Permanente Washington
Anton Pottegård, DMSc PhD, University of Southern Denmark

Daniela Moga, MD, PhD, University of Kentucky
Andrew Zullo, PharmD, PhD, Brown University

Register at:

Presented by the International Society for Pharmacoepidemiology (ISPE) and co-sponsored by the Australian Deprescribing Network (ADeN) and the US Deprescribing Research Network (USDeN).

Description: Deprescribing, the clinically supervised process of tapering or stopping medications with the goal of minimizing inappropriate medication use and improving patient outcomes, has gained significant attention in the last decade. While deprescribing has been mostly used as a solution to address inappropriate medication use and polypharmacy in older adults, there is growing evidence of its utility throughout the lifespan. In addition, finding the appropriate methodological approach in evaluating the impact of deprescribing interventions on health-related outcomes is a topic of interest for clinicians and pharmacoepidemiologists all around the world. Existing Deprescribing Networks (Canadian Deprescribing Network- CaDeN, US Deprescribing Research Network- USDeN, Australian Deprescribing Network- ADeN, or the Network of European Researchers in Deprescribing – NERD) provide valuable resources for clinicians and researchers. Some of these networks provide useful clinical tools, such as evidence-based guidance for implementing deprescribing protocols in clinical practice, while others focus on researchers, offering training opportunities, pilot funding, and tools for conducting research. The evidence to support deprescribing efforts is based on research showing a wide variety of negative health effects of inappropriate medications and polypharmacy, as well as randomized trials testing the efficacy and/or effectiveness of deprescribing interventions on reducing the use of targeted medications. However, clinical studies of medication withdrawal are limited due to challenges in recruitment and retention of participants, as well as limited power to study clinical outcomes and often limited measures of patient-centered outcomes that matter for patients and their caregivers. Pharmacoepidemiology and real-world data have been widely used in an effort to address limitations of smaller scale clinical studies and provide important insights on the real-world evidence of different interventions. The session will begin with a brief introduction of the topic and the speakers (moderator, 4-5 min) followed by presentations to address:

1.  The existing deprescribing landscape (including existing deprescribing networks throughout the world), current initiatives in clinical and implementation deprescribing research, and the need to incorporate real-world data and observational studies (Dr. Sirois, 12 min)

2.  Recent efforts in operationalizing key variables needed for deprescribing studies using routinely generated healthcare data, including harmonizing measures across different healthcare systems and data types: finding from the US Deprescribing Research Network Data Harmonization Workgroup (Dr. Dublin, 12 min)

3.  Challenges and opportunities in using pharmacoepidemiologic approaches in deprescribing research (Dr. Pottegård, 12 min)

The session will conclude with a call for methodology development and finding ways for data integration to facilitate observational deprescribing research under a causal framework (moderator, 5 min) followed by a Q&A session.

The presentation recording and powerpoint can be accessed at:

FRI | 29 JULY | 10.00 AM AEST

Join us for a Journal Club discussion of a recently published deprescribing article led by 
Dr Emily Reeeve, BPharm, PhD
Senior Research Fellow, Monash University, Australia

Article title: Process evaluation of the SPPiRE trial: a GP delivered medication review of polypharmacy, deprescribing and patient priorities in older people with multimorbidity. 2022, McCarthy C et al. 

FRI | 24 JUNE | 10.00 AM AEST

Deprescribing: Lessons Learned from The MedSafer Cluster Randomized Trial
Emily McDonald, MD MSc (Epi) FRCPC
Associate Professor of Medicine McGill University, Canada

Evidence to Inform Deprescribing: Real-World Example on Anticoagulants and Protocol for Future Guidelines
Kaley Hayes, PharmD PhD
Assistant Professor of Health Services, Policy, and Practice, Brown University, USA

The material in this presentation was approved for ADeN Journal Club member access and is not to be reproduced or copied without permission from the original author. By accessing the link below, you are agreeing to these terms.

Sign up to our monthly email list for upcoming opportunities, news on AGM and more.

* indicates required

Contact us

For general enquiries fill out our online contact form. Copyright 2022. Read our disclaimer.